AKT1 and prostate cancer: TQ has suppressed prostate cancer’s carcinogenesis at 45 μM by reducing IL-6 expression and inhibiting the phosphorylation of STAT3, AKT, and extracellular signal-regulated kinase (ERK) proteins in PC3 prostate cancer cells [89].